TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $23.03 million. The enterprise value is $19.44 million.
| Market Cap | 23.03M |
| Enterprise Value | 19.44M |
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 0.47% in one year.
| Current Share Class | 11.57M |
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | +0.47% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 2.20% |
| Owned by Institutions (%) | 23.42% |
| Float | 9.49M |
Valuation Ratios
The trailing PE ratio is 267.83.
| PE Ratio | 267.83 |
| Forward PE | n/a |
| PS Ratio | 6.87 |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | 8.61 |
| P/OCF Ratio | 8.61 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 108.59 |
| EV / Sales | 5.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 7.27 |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.11 |
| Quick Ratio | 2.37 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.80 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 0.32% and return on invested capital (ROIC) is -5.34%.
| Return on Equity (ROE) | 0.32% |
| Return on Assets (ROA) | -2.95% |
| Return on Invested Capital (ROIC) | -5.34% |
| Return on Capital Employed (ROCE) | -5.48% |
| Weighted Average Cost of Capital (WACC) | 6.25% |
| Revenue Per Employee | $3.35M |
| Profits Per Employee | $179,000 |
| Employee Count | 1 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TherapeuticsMD has paid $32,000 in taxes.
| Income Tax | 32,000 |
| Effective Tax Rate | 27.12% |
Stock Price Statistics
The stock price has increased by +76.11% in the last 52 weeks. The beta is 0.60, so TherapeuticsMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +76.11% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 1.78 |
| Relative Strength Index (RSI) | 41.69 |
| Average Volume (20 Days) | 33,041 |
Short Selling Information
The latest short interest is 53,083, so 0.46% of the outstanding shares have been sold short.
| Short Interest | 53,083 |
| Short Previous Month | 56,765 |
| Short % of Shares Out | 0.46% |
| Short % of Float | 0.56% |
| Short Ratio (days to cover) | 2.44 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $3.35 million and earned $179,000 in profits. Earnings per share was $0.02.
| Revenue | 3.35M |
| Gross Profit | 3.35M |
| Operating Income | -1.79M |
| Pretax Income | 118,000 |
| Net Income | 179,000 |
| EBITDA | -1.41M |
| EBIT | -1.79M |
| Earnings Per Share (EPS) | $0.02 |
Balance Sheet
The company has $8.42 million in cash and $4.82 million in debt, with a net cash position of $3.60 million or $0.31 per share.
| Cash & Cash Equivalents | 8.42M |
| Total Debt | 4.82M |
| Net Cash | 3.60M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 26.97M |
| Book Value Per Share | 2.33 |
| Working Capital | 10.35M |
Cash Flow
| Operating Cash Flow | 2.67M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 383,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 2.67M |
| FCF Per Share | $0.23 |
Margins
Gross margin is 100.00%, with operating and profit margins of -53.39% and 5.34%.
| Gross Margin | 100.00% |
| Operating Margin | -53.39% |
| Pretax Margin | 3.52% |
| Profit Margin | 5.34% |
| EBITDA Margin | -41.96% |
| EBIT Margin | -53.39% |
| FCF Margin | 79.75% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.47% |
| Shareholder Yield | -0.47% |
| Earnings Yield | 0.78% |
| FCF Yield | 11.61% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 47.51% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |